Literature DB >> 14670964

Oxidative cross-linking of tryptophan to glycine restrains matrix metalloproteinase activity: specific structural motifs control protein oxidation.

Xiaoyun Fu1, Jeff L F Kao, Constanze Bergt, Sean Y Kassim, Nabiha P Huq, André d'Avignon, William C Parks, Robert P Mecham, Jay W Heinecke.   

Abstract

Matrix metalloproteinases (MMPs) function in homeostatic and repair processes, but unregulated catalysis by these extracellular proteinases leads to the pathological destruction of tissue proteins. An important mechanism for controlling enzyme activity might involve hypochlorous acid (HOCl), a potent oxidant produced by the myeloperoxidase system of phagocytes. We have shown that inactivation of MMP-7 (matrilysin) by HOCl coincides with the formation of a novel oxidation product, WG-4, through modification of adjacent tryptophan and glycine residues and loss of 4 atomic mass units. Here, we use mass spectrometry, UV/visible spectroscopy, hydrogen-deuterium exchange, and NMR spectroscopy to investigate the formation and structure of WG-4. For the initial step, HOCl chlorinates the indole ring of tryptophan. The resulting 3-chloroindolenine generates a previously unknown cyclic indole-amide species, in which tryptophan cross-links to the main chain nitrogen of the adjacent glycine residue to form an aromatic six-membered ring. WG-4 kinks and stiffens the peptide backbone, which may hinder the interaction of substrate with the catalytic pocket of MMP-7. Our observations indicate that specific structural motifs are important for controlling protein modification by oxidants and suggest that pericellular oxidant production by phagocytes might limit MMP activity during inflammation.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14670964     DOI: 10.1074/jbc.C300506200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  25 in total

Review 1.  Matrix metalloproteinase inhibitors as investigative tools in the pathogenesis and management of vascular disease.

Authors:  Mina M Benjamin; Raouf A Khalil
Journal:  Exp Suppl       Date:  2012

Review 2.  Matrix Metalloproteinases as Regulators of Vein Structure and Function: Implications in Chronic Venous Disease.

Authors:  Elisabeth MacColl; Raouf A Khalil
Journal:  J Pharmacol Exp Ther       Date:  2015-08-28       Impact factor: 4.030

Review 3.  Mechanisms of I/R-Induced Endothelium-Dependent Vasodilator Dysfunction.

Authors:  Ronald J Korthuis
Journal:  Adv Pharmacol       Date:  2017-12-08

Review 4.  Matrix Metalloproteinases, Vascular Remodeling, and Vascular Disease.

Authors:  Xi Wang; Raouf A Khalil
Journal:  Adv Pharmacol       Date:  2017-09-19

Review 5.  Control of matrix metalloproteinase catalytic activity.

Authors:  Hyun-Jeong Ra; William C Parks
Journal:  Matrix Biol       Date:  2007-07-07       Impact factor: 11.583

Review 6.  Limitations in bonding to dentin and experimental strategies to prevent bond degradation.

Authors:  Y Liu; L Tjäderhane; L Breschi; A Mazzoni; N Li; J Mao; D H Pashley; F R Tay
Journal:  J Dent Res       Date:  2011-01-10       Impact factor: 6.116

Review 7.  Matrix Metalloproteinase Inhibitors as Investigational and Therapeutic Tools in Unrestrained Tissue Remodeling and Pathological Disorders.

Authors:  Jie Liu; Raouf A Khalil
Journal:  Prog Mol Biol Transl Sci       Date:  2017-05-10       Impact factor: 3.622

Review 8.  Matrix metalloproteinases as potential targets in the venous dilation associated with varicose veins.

Authors:  Arda Kucukguven; Raouf A Khalil
Journal:  Curr Drug Targets       Date:  2013-03       Impact factor: 3.465

9.  Dual functionality of myeloperoxidase in rotenone-exposed brain-resident immune cells.

Authors:  Chi Young Chang; Mi Jeon Song; Sae-Bom Jeon; Hee Jung Yoon; Dae Kee Lee; In-Hoo Kim; Kyungho Suk; Dong-Kug Choi; Eun Jung Park
Journal:  Am J Pathol       Date:  2011-06-23       Impact factor: 4.307

Review 10.  Tumor macrophage redox and effector mechanisms associated with hypoxia.

Authors:  Michael Graham Espey
Journal:  Free Radic Biol Med       Date:  2006-09-16       Impact factor: 7.376

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.